Content Methadone : what & why ? Outcome over 12 years Issues - - PowerPoint PPT Presentation

content
SMART_READER_LITE
LIVE PREVIEW

Content Methadone : what & why ? Outcome over 12 years Issues - - PowerPoint PPT Presentation

Content Methadone : what & why ? Outcome over 12 years Issues of methadone treatment & men in Malaysia Conclusion INTRODUCTION Malaysia Substance use is mainly a problem among men Implications of substance use


slide-1
SLIDE 1

Content

  • Methadone : what &

why ?

  • Outcome over 12 years
  • Issues of methadone

treatment & men in Malaysia

  • Conclusion
slide-2
SLIDE 2

INTRODUCTION

◼ Malaysia ◼ Substance use is mainly a problem among men ◼ Implications of substance use :everybody ◼ Estimated 170,000 people inject drug in the

country

◼ Commonly used illicit substances are heroin,

amphetamine, marijuana & designer drugs

◼ Methadone is one of medical treatment for heroin

use

slide-3
SLIDE 3

Classification of opioids

Classification Types Full agonists Heroin, morphine, methadone, codeine Partial agonists Buprenorphine Antagonist Naltrexone, naloxone

slide-4
SLIDE 4

History of DST in Malaysia

DST is a part of harm reduction approach taken to reduce drug related harm

  • 1995: Naltrexone
  • 2001: Buprenorphine
  • 2005: Methadone
  • 2007: Buprenorphine/Naloxone (Suboxone)

Methadone re classified as Poison

slide-5
SLIDE 5

Comparison among DSTs

slide-6
SLIDE 6

DST : Benefit

  • High

rates

  • f

retention

  • f

patients are achieved and an opportunity is provided for individuals to deal with major health, psychological, family, housing, employment, financial and legal issues while undergoing treatment.

  • Provides opportunities for early diagnosis of
  • ther

health problems, HIV testing and counseling and referral for additional services.

slide-7
SLIDE 7

Methadone

  • Used as treatment for
  • piate dependent since

1970’s

  • In Msia: started since 2005

as part of harm reduction strategies against HIV

  • Taken daily
  • Half life : 16-36 hrs
  • Syrup form
  • Cheap
slide-8
SLIDE 8

Release of dopamine in brain

slide-9
SLIDE 9
slide-10
SLIDE 10

Hypodopaminaemia

Positron emission tomography:

  • The striatum (which contains

the reward and motor circuitry) shows up as bright red and yellow in the controls (in the left column), indicating numerous dopamine D2 receptors.

  • Conversely, the brains of

addicted individuals (in the right column) show a less intense signal, indicating lower levels of dopamine D2 receptors.

Pike VW. J Psychopharmacology 1993

slide-11
SLIDE 11

This is how opiates activate the reward system using the nucleus accumbens as an example. Three neurons participate in opiate action; the dopamine terminal, another terminal (on the right) containing a different neurotransmitter (probably GABA), and the post-synaptic cell containing dopamine receptors. Opiates bind to opiate receptors (green) on the neighboring terminal and this sends a signal to the dopamine terminal to release more

  • dopamine. [One theory is that opiate receptor activation decreases GABA release, which

normally inhibits dopamine release - so dopamine release is increased.]

slide-12
SLIDE 12
slide-13
SLIDE 13
slide-14
SLIDE 14

DRUG ADDICTION IS A COMPLEX ILLNESS A shift from moral model to disease model

slide-15
SLIDE 15

Common features of patients who use illicit drugs:

  • Stigmatized
  • Drug related crimes
  • Unstable marriage
  • Unstable economy
  • Repeatedly incarcerated
  • Polydrug users / problem with alcohol
  • Can’t forget the joy of taking drug
  • Poor coping mechanism
  • Low self esteem
  • Low motivation level
  • Multiple co morbidities
slide-16
SLIDE 16

With effective intervention In place. 300,000 HIV/AIDS cases by 2015 If no Effective intervention in place

Projection Of cumulative HIV/AIDS cases

YEAR 2010 2015 2005 300,000 100,000

The expected reduction of HIV/AIDS cases

1985

HIV/AIDS Projection by 2015, Malaysia

Estimated Prevalence: 1.3% - Estimated PLWHAs: 188,838

slide-17
SLIDE 17
  • 2. Screening and medical treatment
  • 4. Needle Syringe Exchange Program

(NSEP)

  • 5. Safe Sex (Condom use)

VCT COUNCELING DRUG REHAB ARV Rx. STD Rx. SOCIAL WELFARE HEALTH & MEDICAL CARE JOB PLACEMENT

COMPONENT OF HARM REDUCTION

IEC

  • 1. Education
  • 3. Methadone Maintenance Therapy

(MMT)

slide-18
SLIDE 18

DST FACILITIES, MALAYSIA 2017

DST (Commenced : Oct 2005) Number of DST Facility (Cumulative by Years) 2011 2012 2013 2014 2015 2016 2017 Hospital 48 49 53 55 55 55 53 Health Clinic 168 203 293 316 359 387 398 G.P (MoH partnership) 24 21 22 24 24 22 22 NADA 32 41 59 58 25* 24 24 Prison 18 18 18 18 18 17 22 Others 2 1 1 1 1 1 1 Total Govt 292 333 446 472 482 506 520 G.P Setting 382 382 365 366 375 401 369 TOTAL 674 715 811 838 857 907 889

Source : Ministry of Health, Malaysia

slide-19
SLIDE 19

COVERAGE : DST PATIENTS 2017

DST (Commenced : Oct 2005) 2011 2012 2013 2014 2015 2016 2017

  • No. of registered

patient at Govt Setting (Annual) 5,086 6,801 5,688 4,111 3,710 3,064 2,811

  • No. of registered

patient at Govt Setting (Cum) 20,955 27,756 33,444 37,555 41,265 44,329 47,140

  • No. of registered

patient at GP Setting (Cum)* 23,257 * 24,324 * 31,805 ** 37,261 ** 44,361 50,616 52,341 TOTAL 44,212 52,080 65,249 74,816 85,626 94,945 99,481

Source :

  • 1. Disease Control Division, MoH Malaysia
  • 2. * NDST Report, AMAM
  • 3. ** SPIKE System, Pharmaceutical Service

Division, MoH Malaysia

slide-20
SLIDE 20

Outcome of methadone treatment towards men in Malaysia (2005-2017)

slide-21
SLIDE 21

United Nations Office on Drugs and Crime (UNODC)

Engraved as: “Presented to Tampin Health Clinic in recognition of its contribution to promoting community based drug dependence treatment in Southeast Asia July 2012 “

slide-22
SLIDE 22

Changes in HIV landscape, Malaysia 2000 - 2017

Source: HIV/STI /Hep C Sector, Division of Disease Control, Ministry of Health Malaysia

slide-23
SLIDE 23

HIV PREVALENCE AMONG PWID (IBBS) 2009 22.1 % 2012 18.9 % 2014 16.3 % 2017 13.4 %

REPORTED HIV CASES ATTRIBUTED TO IDU, MALAYSIA 2000 - 2017

3,815 4,724 5,176 4,796 4,478 4,038 3,127 2,601 2,113 1,699 1,733 1,348 1,014 728 680 561 377 115

74.7 79.6 74.2 70.6 69.7 66 53.6 57.3 57.2 55.2 47.6 38.7 29.5 21.5 19.3 16.8 11.1 3.44

10 20 30 40 50 60 70 80 90 1,000 2,000 3,000 4,000 5,000 6,000 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

Notification rate No Year

HIV IDU Notification rate

Source : MoH Malaysia

slide-24
SLIDE 24

MALAYSIAN METHADONE TREATMENT OUTCOME STUDY (MyTOS) 2016

  • NMRR: 13-1270-18045 ( 15th May 2014)
  • MRG-MOH-2014-10 (28th Aug 2014)
slide-25
SLIDE 25

Socio demographic characteristic Count % Sex (n=3254) Male 3223 99.0 Female 31 1.0 Ethnicity (n=3254) Malay 2862 85.9 Chinese 261 9.3 Indian 116 4.3 Others 15 0.2 Marital Status(n=3254) Married 1420 42 Widowed 36 1.0 Divorced 230 7.6 Separated 16 0.5 Cohabiting 3 0.1 Never Married 1549 48.8

MyTOS 2016

slide-26
SLIDE 26

Status

Status Count Estimated population % Prevalence 95% CI Lower Upper Dead 251 2373 8.6 6.8 10.8 Defaulted 984 8030 29.2 26 32.4 Transferred 546 4831 17.5 14.6 20.8 Active 1234 10243 37.1 33.7 40.7 Terminated voluntarily Terminated involuntarily 221 18 1972 138 7.1 0.5 4.9 0.2 10.3 1.1

Status ( n=3254) Count Estimated population % Prevalence 95% CI Lower Upper Dead 251 2373 8.6 6.8 10.8 Defaulted 984 8030 29.2 26 32.4 Transferred 546 4831 17.5 14.6 20.8 Active 1234 10243 37.1 33.7 40.7 Terminated voluntarily Terminated involuntarily 221 18 1972 138 7.1 0.5 4.9 0.2 10.3 1.1

slide-27
SLIDE 27

HIV risk, crime & health

Items n= 779 Mean ± SD Mean difference ± SE (before vs after) 95% CI t P HIV Risks 6.22 ± 7.24 2.65 ± 4.27 3.56 ± 0.23 3.12 4.00 15.77 <0.001 Crime 0.30 ± 1.10 0.03 ± 0.28 0.30 ± 0.03 0.24 0.37 9.11 <0.001 Health score 3.94 ± 4.50 2.22 ± 3.09 1.73 ± 0.13 1.47 1.98 13.37 <0.001

slide-28
SLIDE 28

Blood borne viruses infection

BBV n Baseline Current Positive n (%) Negative n (%) Positive n (%) Negative n (%) HIV 1200 162 (13.5) 1038 (86.5) 168 (14.0) 1032 (86.0) Hep B 1183 59 (5.0) 1124 (95.0) 62 (5.2) 1121 (94.8) Hep C 1088 686 (63.1) 402 (36.9) 703 (64.6) 385 (35.4)

slide-29
SLIDE 29

Drug / substans use

Items n= 779 Mean ± SD Mean difference ± SE (before vs after) 95% CI t P Before After Min Max Heroin 2.70 ± 2.38 0.003 ± 0.06 2.69 ± 0.08 2.53 2.86 31.62 <0.001 Other opiate 0.05 ± 0.43 0.00 ± 0.00 0.05 ± 0.02 0.02 0.08 3.01 0.002 Alcohol 0.04 ± 0.58 0.00 ± 0.04 0.04 ± 0.02 0.00 0.08 1.99 0.046 Marijuana 0.01 ± 0.26 0.00 ± 0.00 0.01 ± 0.00 0.00 0.03 1.36 0.17 Tranquilizer 0.50 ± 0.68 0.00 ± 0.00 0.05 ± 0.02 0.00 0.10 2.02 0.14 Hallucinogen 0.02 ± 0.24 0.00 ± 0.00 0.02 ± 0.00 0.00 0.36 2.24 0.03 Tobacco 9.53 ± 8.58 0.31 ± 2.05 9.22 ± 0.31 8.61 9.82 30.03 <0.001

slide-30
SLIDE 30

Incarceration

History Before MMT n (%) After MMT n (%) Locked –up(n=868) Yes 506(58.3) 218(25.1) No 362(41.7) 650(74.9) Imprisoned(n=846) Yes 482 (57) 77 (9.1) No 364 (43) 769 (90.9) Involuntary rehabilitation centre(n=831) Yes 229 (27.6) 13 (1.6) No 602 (72.4) 818 (98.4) Incarceration(imprisoned & Involuntary rehabilitation centre)(n=1234) Yes 736 (59.6) 93 (7.5) No 498 (40.4) 1141 (92.5)

slide-31
SLIDE 31

Quality of Life

Variable n= 905 Mean ± SD 95% CI t P Before After Min Max Physical 54.42±15.00 67.18±14.63

  • 13.89
  • 11.61
  • 21.90

<0.001 Psychological 51.06±15.65 66.54±14.81

  • 16.67
  • 14.29
  • 25.4

<0.001 Social 52.79±17.54 65.87±17.14

  • 14.38
  • 11.77
  • 19.65

<0.001 Environmental 50.36±14.52 64.48±15.25

  • 15.21
  • 13.03
  • 25.38

<0.001

slide-32
SLIDE 32

Patient’s perception towards MMT

26.8% 61.9% 6% 3.1% 2.3%

Strongly agree Agree Not sure Disagree Strongly disagree

Question: In MMT, you received assistance that

slide-33
SLIDE 33

Issues regarding methadone treatment

  • Side effects
  • Drug-drug interaction
  • Stigma
  • Long term treatment for chronic disease
  • Existing drug law
  • Insufficient resources to manage behaviour &

fulfilling their psychosocial & spiritual needs

  • Multiple difficult to meet needs
slide-34
SLIDE 34

MyTOS 2016

slide-35
SLIDE 35

Drug-Drug Interaction

ARV TB

slide-36
SLIDE 36

Needs that are to be addressed in

  • rder to stabilize drug addicts
  • These needs are multiple, complex and difficult to meet:
  • Food - Addiction issues - Medical illnesses
  • Shelter - other substances co dependency
  • Occupation - Stigma - HIV -Hep B - Hep C
  • Family - Depression - Anxiety - Psychosis
  • Developing self confidence - to solve legal action
  • Finances - Warts - valvular heart disease - DVT
  • Self believe and trust by family and the community
  • Getting follow up treatment - STIs - TB - peacefulness etc etc etc

etc etc etc etc etc etc etc etc etc etc etc etc

slide-37
SLIDE 37

Conclusion

  • Cost effective treatment
  • Protect from further life complications
  • Good outcome for patient, family & comunity
  • Very little side effects